CClinicalTrials.gg
Sign In
RecruitingNCT00398177Updated Dec 24, 2025

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease

An observational study in Lymphoma, Non-Hodgkin and Hodgkin's Disease, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Stanford University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
9,999
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to characterize the molecular and cell biology of the tumor cells in lymphoma.

Read the detailed description

This research involves the study of lymphoma cells in order to better understand how the disease grows and spreads. This study may lead to the development of special materials that could be used, in the future, to treat lymphoma or to follow the response of lymphoma to treatment.

02

Conditions studied

  • Lymphoma, Non-Hodgkin
  • Hodgkin's Disease
03

In context

Lymphoma, Non-Hodgkin

1,989 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 307 are open to participants now.

This study's planned enrollment of 9,999 is above the median of 150 across 159 observational studies indexed under Lymphoma, Non-Hodgkin.

Browse Lymphoma, Non-Hodgkin studies →

Lead sponsor

Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.

Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any type of NHL or Hodgkin's disease.

Inclusion criteria

  • Diagnosis of Hodgkin's disease or non-Hodgkin's lymphoma, any cellular classification, any stage, any grade.
  • Adult or pediatric patients receiving lymph node excision for purposes other than cancer therapy (i.e. tonsillectomy, sleep apnea).
  • A routine procedure for tissue collection is planned.
  • Ability to understand and the willingness to sign a written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Patients without NHL or Hodgkin's disease
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
9,999 participants (estimated)
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Collection of tumor tissue to characterize the molecular and cell biology of tumor cells in lymphoma.

    Time frame: The study will continue indefinitely.

07

Study locations

1 of 1 sites recruiting
  • Stanford University School of Medicine
    Stanford, California 94305, United States
    • Alyssa M Kanegai · Contact · akanegai@stanford.edu · 650-736-1596
    • Ronald Levy · Principal investigator
    • Shoshana Levy · Sub investigator
    Recruiting
08

References and documents

Publications

  • Roschewski M, Kurtz DM, Westin JR, Lynch RC, Gopal AK, Alig SK, Sworder BJ, Cherng HJ, Kuffer C, Blair D, Brown K, Goldstein JS, Schultz A, Close S, Chabon JJ, Diehn M, Wilson WH, Alizadeh AA. Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. J Clin Oncol. 2025 Dec;43(34):3652-3661. doi: 10.1200/JCO-25-01534. Epub 2025 Aug 13. PubMed 40802906 ↗
  • Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Duhrsen U, Huttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2018 Oct 1;36(28):2845-2853. doi: 10.1200/JCO.2018.78.5246. Epub 2018 Aug 20. PubMed 30125215 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00398177
Lead sponsor
Stanford University
Collaborators
The Leukemia and Lymphoma Society, Biospect Inc
Responsible party
Sponsor
First posted
Nov 10, 2006
Start date
Jan 1999
Primary completion
Jan 2099 (estimated)
Completion
Jan 2099 (estimated)
Last update
Dec 24, 2025

Study contacts

Alyssa M Kanegai
Contact
akanegai@stanford.edu
650-736-1596
Ronald Levy, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lymphoma, Non-Hodgkin→

Other studies from this sponsor

Stanford University

Start the discussion